The Journal of family practice
-
At the end of the activity, participants will be able to: • Recognize obesity as a chronic, relapsing, serious disease warranting long-term management and early intervention to minimize disease burden and decrease associated morbidity and mortality. • Destigmatize obesity to initiate and enhance patient engagement. • Apply guideline-recommended care for screening, diagnosis, and individualized treatment of adults and others with obesity. • Incorporate practical practice management strategies.
-
• Collaborate with patients to inform treatment decision-making that addresses their symptoms, goals, and concerns • Individualize guideline-recommended therapy to reduce chronic obstructive pulmonary disease (COPD) exacerbations, improve lung function, manage daily symptoms such as breathlessness, and help achieve the patient's goals • Select an inhaler and an optimal dose of medication to best meet a patient's needs and capabilities.
-
At the end of the activity, participants will be able to: • Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). • Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. • Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. • Describe the benefits and limitations of the steroidal and nonsteroidal mineralocorticoid receptor antagonists in the treatment of patients with DKD.
-
Intensifying hypertension regimens at discharge increases risk in older patients.
-
Practice Guideline
National Asthma Education and Prevention Program 2020 Guidelines: What's Important for Primary Care.
• The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group provides updated recommendations for 6 topics related to the management of individuals with asthma. • The classification of asthma severity and asthma control, as well as the concept of utilizing a stepwise approach to pharmacologic treatment, were not updated from the Expert Panel Report 3, released in 2007. • However, important updates in preferred therapies for intermittent and persistent asthma at treatment steps 1 through 5 were suggested. • Recommendations regarding biologic therapy were not included in the 2020 update, as only evidence and US Food and Drug Administration approvals through October 2018 were considered. • The most recent 2021 Global Initiative for Asthma guidelines are not included in this review but can be used in a complementary manner to assist primary care clinicians to optimize decisions regarding the care of patients with asthma.